The Latest Breaking News from AstraZeneca

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Speaking publicly for the first time, her family say they fully support the COVID-19 vaccine rollout, but believe the government should have had a better plan to support families like theirs.

It means people with aggressive lung cancer can see their life expectancy go from two and half to five years

President Joe Biden will appeal for a renewed international commitment to attacking COVID-19 as the second global COVID-19 summit opens

In recent months there have been positive signs that the world is returning to normal after the Covid-19 pandemic. People have worked tirelessly over the past two years to address and mitigate the consequences of the pandemic, spending billions on healthcare, vaccine development and deployment, social assistance payments, and other…

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

The renowned immunologist remains as upbeat about jabs – and UK life science – as he was in the depths of the pandemic

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

AstraZeneca has become a household name thanks to its Covid-19 vaccine, though the company produces many other drugs to justify its $200 billion market cap.

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill